Medicamen Biotech zooms on the BSE
Medicamen Biotech is currently trading at Rs. 507.90, up by 27.35 points or 5.69% from its previous closing of Rs. 480.55 on the BSE.
The scrip opened at Rs. 497.35 and has touched a high and low of Rs. 538.00 and Rs. 492.70 respectively. So far 3144 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 903.50 on 11-Aug-2023 and a 52 week low of Rs. 356.75 on 13-Mar-2024.
Last one week high and low of the scrip stood at Rs. 540.95 and Rs. 475.50 respectively. The current market cap of the company is Rs. 645.77 crore.
The promoters holding in the company stood at 43.21%, while Institutions and Non-Institutions held 1.10% and 55.69% respectively.
The Inspection Department, Division of Production & Distribution Control, National Organisation for Medicines, GREECE, has inspected the General Tablets and Liquid Orals Formulation facility of Medicamen Biotech located at Phase IV, Industrial Area, Bhiwadi from May 28, 2024 and concluded on May 30, 2024.
The inspection closed with some procedural observations which will be well responded within Stipulated time. However, the Final approval (EU GMP Certification) is expected after submission of formal response to Greece Authorities.
Medicamen Biotech is engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets.
